Felzartamab
Sponsors
Istituto Di Ricerche Farmacologiche Mario Negri, Biogen Idec Research Limited, Farsad Eskandary, HI-Bio, A Biogen Company, Biogen
Conditions
Antibody-mediated RejectionIgA nephropathyImmunoglobulin A (IgA) NephropathyImmunoglobulin A Nephropathy (IgAN)Kidney Transplant Recipients with Late Antibody-Mediated RejectionLupus NephritisMembranous nephropathyMicrovascular Inflammation
Phase 1
Phase 2
Felzartamab in Late Antibody-Mediated Rejection
CompletedNCT05021484
Start: 2021-10-06End: 2024-03-07Updated: 2024-04-18
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
CompletedNCT05065970
Start: 2021-08-31End: 2024-05-06Updated: 2025-02-07
Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Therapy (MONET study)
CompletedCTIS2024-513744-28-00
Start: 2021-10-22End: 2025-02-21Target: 10Updated: 2024-09-25
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
RecruitingNCT07219043
Start: 2026-01-05End: 2028-02-10Target: 81Updated: 2026-04-03
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI)- (299AR201-TRANSPIRE)
Not yet recruitingCTIS2025-521742-15-00
Target: 13Updated: 2026-02-10
Phase 3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
RecruitingNCT06685757
Start: 2024-12-03End: 2027-06-01Target: 120Updated: 2026-03-12
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
RecruitingNCT06935357
Start: 2025-05-08End: 2029-06-05Target: 454Updated: 2026-04-01
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
RecruitingNCT06962800
Start: 2025-05-22End: 2029-03-29Target: 180Updated: 2026-04-02
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3
Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late
Antibody-Mediated Rejection (AMR) (TRANSCEND / 299AR301)
RecruitingCTIS2024-519095-66-00
Start: 2025-07-23Target: 49Updated: 2025-12-04
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL)
RecruitingCTIS2024-519345-30-00
Start: 2025-11-12Target: 201Updated: 2025-10-30
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
Not yet recruitingNCT07444489
Start: 2026-03-10End: 2031-05-28Target: 120Updated: 2026-03-03